Cyberonics responds to warning letter:
This article was originally published in Clinica
Executive Summary
Cyberonics says it has responded to the FDA's warning letter, issued on December 22 2004. The agency had said the company's three written responses to a number of Form-483 inspectional observations had failed to address satisfactorily the relevant issues. CEO Robert Cummins said the response was lengthy and outlined measures taken and to be taken by the firm to improve its quality systems. The company is still hoping to receive PMA approval for its vagus nerve stimulation device for use in depression by the end of January, although a decision could be delayed until late March; the original PMA was rejected last August.
You may also be interested in...
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.